Physician profile
James Jonathan Slater
NPI 1942497466
$3,978.82
in general payments reported to CMS, 2019-2025
29 companies · $786 in 2025
The $786 reported for 2025 was more than what 76% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $31.27 · 2021: $582 · 2022: $869 · 2023: $1,031 · 2024: $574 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $433.29 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $411.56 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $373.09 | 2022-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Kaleo, INC. | $354.28 | 2021-2023 | Auvi-Q |
| Stryker Corporation | $332.63 | 2021-2022 | |
| Genzyme Corporation | $326.99 | 2021-2025 | |
| Aerin Medical INC. | $285.65 | 2022-2024 | |
| Grifols USA, LLC | $188.01 | 2021-2024 | Xembify |
| Octapharma USA, INC. | $147.09 | 2023-2024 | Cutaquig |
| Astrazeneca Pharmaceuticals LP | $127.92 | 2023-2025 | Tezspire, Fasenra, Airsupra |
| Blueprint Medicines Corporation | $124.30 | 2024-2025 | Ayvakit |
| Incyte Corporation | $111.97 | 2021-2024 | Opzelura |
| Intersect Ent, INC. | $106.13 | 2019 | |
| Genentech USA, INC. | $105.45 | 2023-2025 | Xolair |
| Csl Behring | $82.73 | 2021-2025 | Hizentra, Haegarda |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $82.10 | 2021-2025 | Hyqvia, Elaprase |
| Acclarent, INC | $68.49 | 2020-2021 | |
| Pharming Healthcare, INC. | $53.23 | 2025 | Ruconest |
| Hikma Pharmaceuticals USA | $50.64 | 2022-2023 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $45.27 | 2022-2025 | |
| Medtronic, INC. | $32.73 | 2023-2025 | Stealthstation S8 Platform, Sinuva |
| Inspire Medical Systems, INC. | $24.44 | 2023 | Inspire |
| Cycle Pharmaceuticals INC | $20.70 | 2025 | Sajazir |
| Smith+Nephew, INC. | $17.79 | 2025 | Tula |
| Ars Pharmaceuticals Operations, INC. | $16.88 | 2025 | Neffy |
| Azurity Pharmaceuticals, INC. | $15.91 | 2025 | Alvesco |
| Phadia US INC. | $14.37 | 2024 | Immunocap |
| Aimmune Therapeutics, INC. | $14.13 | 2022 | |
| Alk-Abello, INC | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Slater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.